Karolinska Development AB ser.B
Karolinska Development AB (publ): New date for publication of Karolinska Developments Interim Report January June 2019
STOCKHOLM, SWEDEN 16 August 2019. Karolinska Development AB (Karolinska
Development or the Company) hereby announces that the Companys Q2
report for the period January June will be published on 30 August 2019.
The previous date of publication was 21 August 2019.
For more information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73982 52 02, e-mail: email@example.com
Fredrik Järrsten, CFO and deputy CEO, Karolinska Development AB
Phone: +4670496 46 28, e-mail: firstname.lastname@example.org
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life
sciences investment company. The company focuses on identifying
breakthrough medical innovations that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of
companies that advance these assets into commercial products that are
designed to make a difference to patients lives while providing an
attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research
institutes in the Nordic region. The Company aims to build companies around
scientists who are leaders in their fields, supported by experienced
management teams and advisers, and co-funded by specialist international
investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of ten companies
targeting opportunities in innovative treatment for life-threatening or
serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals
with a proven track record as company builders and with access to a strong
For more information: www.karolinskadevelopment.com
* KD Press release - New date for publication of quarterly report